BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25767039)

  • 1. Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.
    Liu-Chittenden Y; Jain M; Kumar P; Patel D; Aufforth R; Neychev V; Sadowski S; Gara SK; Joshi BH; Cottle-Delisle C; Merkel R; Yang L; Miettinen M; Puri RK; Kebebew E
    Cancer Med; 2015 Jul; 4(7):1060-8. PubMed ID: 25767039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.
    Smith DC; Kroiss M; Kebebew E; Habra MA; Chugh R; Schneider BJ; Fassnacht M; Jafarinasabian P; Ijzerman MM; Lin VH; Mohideen P; Naing A
    Invest New Drugs; 2020 Oct; 38(5):1421-1429. PubMed ID: 31984451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
    Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
    Joshi BH; Kawakami K; Leland P; Puri RK
    Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice.
    Blease K; Jakubzick C; Schuh JM; Joshi BH; Puri RK; Hogaboam CM
    J Immunol; 2001 Dec; 167(11):6583-92. PubMed ID: 11714828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
    Pai LH; Bookman MA; Ozols RF; Young RC; Smith JW; Longo DL; Gould B; Frankel A; McClay EF; Howell S
    J Clin Oncol; 1991 Dec; 9(12):2095-103. PubMed ID: 1960550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
    Garland L; Gitlitz B; Ebbinghaus S; Pan H; de Haan H; Puri RK; Von Hoff D; Figlin R
    J Immunother; 2005; 28(4):376-81. PubMed ID: 16000956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
    Puri RK
    Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
    Haluska P; Worden F; Olmos D; Yin D; Schteingart D; Batzel GN; Paccagnella ML; de Bono JS; Gualberto A; Hammer GD
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):765-73. PubMed ID: 19649631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
    Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
    J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.
    Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM
    PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
    Kawakami K; Husain SR; Kawakami M; Puri RK
    Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
    Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
    Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
    Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
    Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
    Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.